U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539402) titled 'Searching Patterns In the Robustness of Immunological FVIII Tolerance' on April 28, 2025.
Brief Summary: Children with hemophilia A lack clotting factor VIII (FVIII) due to a genetic mutation. It is well known that administration of FVIII concentrate leads to immunological tolerance for the FVIII protein in the majority of children. In 30% of these children tolerance is not achieved leading to the development of anti-FVIII antibodies (i.e. inhibitors). Our knowledge on the underlying immunological mechanisms leading to tolerance is limited. Recently, Non-Factor Therapy (NFT) has become available for prevention of bleeding in patien...